skip to main content

Benign prostatic enlargement treated with finasteride; rising PSA requiring assessment for prostate cancer — M

Instant feedback + full explanation. One question, done properly.

HardBPHBenign prostatic enlargement treated with finasteride; rising PSA requiring assessment for prostate cancerMSRA

A 67-year-old man is reviewed in general practice 9 months after starting finasteride 5 mg daily and tamsulosin MR 400 micrograms daily for bothersome LUTS with a 52 mL prostate. Before treatment, his PSA was 3.0 micrograms/L and DRE was benign. His symptoms have improved and he reports good adherence. PSA at 6 months was 1.5 micrograms/L; a repeat PSA today is 2.4 micrograms/L. Urine dipstick is negative and he has had no urinary infection, catheterisation, ejaculation or vigorous cycling in the preceding 48 hours. DRE remains benign. He is fit for investigation and treatment if needed. What is the most appropriate next management step?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — Make a suspected cancer pathway referral for prostate cancer

Explanation lettering: D = shown as A · E = shown as B · A = shown as C · B = shown as D · C = shown as E

Finasteride lowers PSA by approximately 50% after 6 months or more; measured PSA should therefore be doubled when compared with thresholds used in untreated men. His PSA of 2.4 micrograms/L is equivalent to approximately 4.8 micrograms/L, exceeding the NICE age-specific threshold of 4.5 micrograms/L for a symptomatic man aged 60–69 years. More importantly, PSA has risen from its finasteride-treated nadir (1.5 to 2.4 micrograms/L), despite reported adherence and exclusion of common transient causes. The SmPC states that a sustained PSA rise during finasteride treatment requires careful evaluation. A normal DRE does not negate this risk. A is unsafe because both the adjusted PSA and rising trajectory warrant action now. B is inappropriate: stopping finasteride delays assessment and does not remove the need to investigate a rising PSA. D under-prioritises a possible cancer presentation; the referral pathway should be suspected cancer rather than routine urology. E may form part of subsequent specialist assessment but does not precede indicated cancer-pathway referral; there is no evidence here of retention, renal impairment or upper tract obstruction.

Reference: Finasteride 5mg Tablets - Summary of Product Characteristics, section 4.4 Effects on PSA and prostate cancer detection (2025) — https://www.medicines.org.uk/emc/product/547/smpc NICE NG12 Suspected cancer: recognition and referral, prostate cancer recommendations 1.6.2–1.6.3 and table 2 (Last updated 15 April 2026) — https://www.nice.org.uk/guidance/ng12/chapter/recommendations-organised-by-site-of-cancer